Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2017 /
Treatment choices for HER2 amplified colorectal cancer

1st - 5th Apr 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.04.17
Views: 975

Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy

Dr Marsoni speaks with ecancer at AACR 2017 about the use of patient-derived xenografts of colorectal cancer to identify the role of HER2 amplification in cetuximab-resistant tumour types.

She describes how a combination of lapatanib and trastuzumab can overcome this mutation, based on their success in treating HER2 breast cancer, and taking these results into treating patients can result in tumour shrinkage, and even complete responses.

Dr Marsoni presented these findings at a press conference session, available here.

HER2 mutations in colorectal cancer are also discussed by Dr Hyman in his assessment of neratinib for solid tumours,

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence